Lonza Launches New Operating Model to Power ‘One Lonza’ Vision and Streamline CDMO Business

Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy Previous divisional structure ...

April 02, 2025 | Wednesday | News
Regeneron and Sanofi Receive Approval for Dupixent® in Japan to Treat Chronic Obstructive Pulmonary Disease (COPD)

TARRYTOWN -- Regeneron Pharmaceuticals, and Sanofi announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan ...

March 31, 2025 | Monday | News
CHMP Recommends Opdivo® for EU Approval as Neoadjuvant and Adjuvant Treatment for Resectable NSCLC

Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a...

March 31, 2025 | Monday | News
AstraZeneca’s Calquence® Combination Therapy Recommended for EU Approval in Untreated Mantle Cell Lymphoma

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Un...

March 31, 2025 | Monday | News
Novartis Announces FDA Approval for Expanded Use of Pluvicto® in mCRPC, Tripling Eligible Patient Access

Novartis announced that the US Food and Drug Administration (FDA) approved Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) for patients with pro...

March 31, 2025 | Monday | News
Merck Reports Positive Phase 3 Results for Subcutaneous Pembrolizumab in Metastatic NSCLC

Merck known as MSD outside of the United States and Canada, announced the first data presentation from the pivotal 3475A-D77 Phase 3 trial, evaluating the ...

March 28, 2025 | Friday | News
New Data at ELCC 2025 Reinforces Tagrisso's Role in Treating EGFR-Mutated Lung Cancer Across Stages

New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso...

March 26, 2025 | Wednesday | Reports
FDA Fast-Tracks Tolebrutinib Review for Non-Relapsing Secondary Progressive MS Treatment

The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing secondary pr...

March 26, 2025 | Wednesday | News
CStone Pharmaceuticals Submits EMA Application for Sugemalimab to Treat Unresectable Stage III NSCLC

CStone Pharmaceuticals, a biopharmaceutical company dedicated to developing innovative cancer therapies, announced the submission of a Type II variati...

March 24, 2025 | Monday | News
Terumo Neuro Celebrates 15th Anniversary of WEB™ Aneurysm Embolization System, Revolutionizing Aneurysm Treatment

Terumo Neuro, a global leader in neurovascular innovation and a wholly-owned subsidiary of Terumo Corporation, proudly celebrates the 15th anniversary of t...

March 24, 2025 | Monday | News
Novartis Wins FDA Approval for Fabhalta®, First Oral Therapy for C3G

Novartis announced that oral Fabhalta® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with ...

March 24, 2025 | Monday | News
Bristol Myers Squibb Secures European Approval for Breyanzi® in Relapsed or Refractory Follicular Lymphoma

 Bristol Myers Squibb  announced that the European Commission (EC) has granted approval to Breyanzi® (lisocabtagene maraleucel; lis...

March 18, 2025 | Tuesday | News
Roche Opens Genentech Innovation Center in Boston, Expands Harvard R&D and AI Collaboration

Roche  announced  the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston which will ...

March 10, 2025 | Monday | News
Belén Garijo Leads Merck Back to Profitable Growth, Delivering Strong 2024 Performance

  Key Financial Highlights: Full-year net sales increased to €21.2 billion (organically: +2.0%) EBITDA pre rose to €6.1 billion (orga...

March 06, 2025 | Thursday | Company results

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close